Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.66 |
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 4/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1841842 | 0.98 | TAAR1 (0.68) | TAAR1PARP1NISCHSIRT2HTR2A | |
| SCHEMBL24222406 | 0.82 | TAAR1 (0.68) | TAAR1PARP1NISCHSIRT2HTR2A | |
| SCHEMBL2246257 | 0.81 | TAAR1 (0.97) | TAAR1PARP1NISCHSIRT2HTR2A | |
| SCHEMBL31020998 | 0.81 | TAAR1 (0.66) | TAAR1PARP1NISCHSIRT2HTR2A | |
| SCHEMBL2247036 | 0.81 | TAAR1 (0.66) | TAAR1PARP1NISCHSIRT2HTR2A | |
| SCHEMBL21154445 | 0.81 | TAAR1 (0.66) | TAAR1PARP1NISCHSIRT2HTR2A | |
| SCHEMBL1991623 | 0.81 | NISCH (0.77) | TAAR1PARP1NISCHSIRT2HTR2A | |
| Hydrochloric Acid SCHEMBL1841812 | 0.79 | TAAR1 (0.68) | TAAR1PARP1NISCHSIRT2HTR2A | |
| Hydrochloric Acid SCHEMBL3314590 | 0.79 | NISCH (0.75) | TAAR1PARP1NISCHSIRT2HTR2A | |
| SCHEMBL1844351 | 0.78 | TAAR1 (0.62) | TAAR1PARP1NISCHSIRT2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024924-A1 | SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2022-01-27 | — | — | US | disclosed |
| WO-2020112941-A2 | SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF | TEVA CZECH INDUSTRIES S.R.O (CZ) | 2020-06-04 | — | — | WO | disclosed |
| EP-1581221-B1 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-1581221-A4 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2008-11-26 | — | — | EP | disclosed |
| US-7109339-B2 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1581221-A2 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040180875-A1 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| WO-2004056324-A2 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024924-A1 | SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF | RALA, TACR1, SRM | TAAR1 828/4885PARP1 4453/4885NISCH 5/4885 |
| US-20040180875-A1 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | HTR1A, HTR7, HTR5A | TAAR1 123/4885PARP1 1411/4885NISCH 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.